VUMERITY
effectiveness

Understanding the potential benefits

In clinical trials, a medication called dimethyl fumarate (DMF) was tested in people with relapsing-remitting MS. Once it’s processed in the body, VUMERITY® (diroximel fumarate) takes the same active form as DMF. The information from the clinical trials is DMF data.

Keep reading to learn how VUMERITY may be an effective relapsing MS treatment.

Two
separate studies

Each study
lasted two years

Over 1,500
people

STUDY 1
VUMERITY pill

410 people
took 240 mg of DMF twice a day

Placebo pill

408 people
took a placebo

STUDY 2
VUMERITY pill

359 people
took 240 mg of DMF twice a day

Placebo pill

363 people
took a placebo

VUMERITY is a pill that
helps in three ways

Cuts relapses

More than 70% of people taking DMF had no relapses after two years. Reducing the risk of relapses should be one of the goals of treatment. Although no relapsing MS medication completely gets rid of relapses, DMF has been shown to reduce relapses compared with placebo.

were relapse-free

73% of people taking DMF were relapse-free after 2 years
compared with 54% of people taking placebo.

less likely to relapse

People taking DMF were 49% less likely to have a relapse
compared with placebo.*

fewer relapses

DMF cut the number of relapses by 53%
compared with placebo.

*27% of people taking DMF had a relapse vs 46% taking placebo.
DMF 0.172, placebo 0.364.

were relapse-free

71% of people taking DMF were relapse-free after 2 years
compared with 59% of people taking placebo.

less likely to relapse

People taking DMF were 34% less likely to have a relapse
compared with placebo.*

fewer relapses

DMF cut the number of relapses by 44%
compared with placebo.

*29% of people taking DMF had a relapse vs 41% taking placebo.
DMF 0.224, placebo 0.401.

Disability progression
was less likely

DMF was shown to delay the progression of disability, which is an important goal of treatment.

84% of patients had no disability progression
while taking DMF compared with 73% of people taking placebo.

Disability progression was 38% less likely
for people taking DMF compared with placebo.

Disability progression was 21% less likely
13% of people taking dimethyl fumarate experienced disability progression, compared with 17% taking placebo. There was no statistically significant effect on disability progression in Study 2.

Slows the development of
brain lesions

To understand the impact of DMF on brain lesions, researchers looked at lesions using three different MRI techniques to determine the age and stage of the lesions. Based on all three measures, people taking DMF had fewer lesions compared with those taking placebo. The link between brain lesions and the progression of relapsing MS has not been confirmed. Talking to your healthcare provider about the results of your MRI could help with the management of your relapsing MS.

ACTIVE INFLAMMATION LONG-TERM IMPACT OF INFLAMMATION POSSIBLE PERMANENT DAMAGE
AVERAGE NUMBER OVER 2 YEARS

ACTIVE INFLAMMATION

down arrow

fewer Gd+ lesions for DMF

1.8 placebo

VS

0.1 DMF

LONG-TERM IMPACT OF INFLAMMATION

down arrow

fewer T2 lesions for DMF

17.0 placebo

VS

2.6 DMF

POSSIBLE PERMANENT DAMAGE

down arrow

fewer T1 lesions for
DMF

5.6 placebo

VS

1.5 DMF

ACTIVE INFLAMMATION LONG-TERM IMPACT OF INFLAMMATION POSSIBLE PERMANENT DAMAGE
AVERAGE NUMBER OVER 2 YEARS

ACTIVE INFLAMMATION

down arrow

fewer Gd+ lesions for DMF

2.0 placebo

VS

0.5 DMF

LONG-TERM IMPACT OF INFLAMMATION

down arrow

fewer T2 lesions for DMF

17.4 placebo

VS

5.1 DMF

POSSIBLE PERMANENT DAMAGE

down arrow

fewer T1 lesions for
DMF

7.0 placebo

VS

3.0 DMF